Cynvec

Cynvec is a biotechnology company that specialized in the development of a novel class of cancer therapeutics based on a proprietary Sindbis virus vector platform. The company's technology leverages the natural affinity of the Sindbis virus for the 67-kDa laminin receptor (67LR), which is significantly overexpressed in a wide variety of human cancers. This targeted approach allows for the delivery of therapeutic genes or the induction of apoptosis specifically in tumor cells while minimizing damage to healthy tissue. Cynvec's lead research programs were directed toward indications such as ovarian cancer, melanoma, and glioblastoma. The company originated from extensive research conducted at the New York University School of Medicine and aimed to translate these viral vector discoveries into clinical applications.